{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:32:47Z","timestamp":1783780367245,"version":"3.55.0"},"reference-count":52,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To examine the reported incidence and features of disseminated varicella zoster virus (VZV) infection following live attenuated herpes zoster vaccine live (ZVL: Zostavax, Merck) in immunocompromised people in Australia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and setting<\/jats:title><jats:p>ZVL was funded in 2016 in Australia for people aged 70 years, with a catch-up programme for those 71\u201379 years. From 2016 to 2020, three deaths due to disseminated vaccine-strain VZV infection occurred following inadvertent ZVL administration in individuals with varying levels of immunocompromise. This descriptive study examined 4\u2009years of national surveillance data reported to the Therapeutic Goods Administration\u2019s Adverse Event Monitoring System (AEMS). Denominator data for rates were from doses recorded in the Australian Immunisation Register.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Individuals vaccinated between 1 November 2016 and 31 December 2020 who experienced adverse event(s) following immunisation (AEFI) after ZVL recorded in the AEMS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Primary and secondary outcome measures<\/jats:title><jats:p>Rates and outcomes of confirmed (Oka strain positive) or probable disseminated VZV infection, and inadvertent administration of ZVL in immunocompromised individuals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>854 AEFI were reported from 1\u2009089\u2009966 doses of ZVL administered (78.4 per 100\u2009000 doses). Of those, 14 were classified as confirmed (n=6, 0.55 per 100 000) or probable (n=8) disseminated VZV infection. The confirmed cases were all hospitalised, and most (5\/6) were immunocompromised; three cases died. Thirty-seven individuals were reported as vaccinated despite a contraindication due to immunocompromise (3.4 per 100 000), with 12\/37 (32%) hospitalised.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Disseminated VZV is potentially life-threatening and occurs mostly in those with severe immunocompromise. Inadvertent administration of ZVL to immunocompromised individuals has occurred despite initial provider guidance and education. Multiple additional strategies to assist providers to identify contraindications have been implemented to prevent adverse outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2022-067287","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T15:41:08Z","timestamp":1674834068000},"page":"e067287","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Disseminated varicella zoster virus infection following live attenuated herpes zoster vaccine: descriptive analysis of reports to Australia\u2019s spontaneous vaccine pharmacovigilance system, 2016\u20132020"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1632-0431","authenticated-orcid":false,"given":"Jean","family":"Li-Kim-Moy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaide","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Jayasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brynley P","family":"Hull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7178-8606","authenticated-orcid":false,"given":"Aditi","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank H","family":"Beard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Hickie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4675-0232","authenticated-orcid":false,"given":"Kristine","family":"Macartney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"key":"2023012707402124000_13.1.e067287.1","doi-asserted-by":"crossref","unstructured":"MacIntyre R , Stein A , Harrison C , et al . Increasing trends of herpes zoster in australia. PLOS ONE 2015;10:e0125025. doi:10.1371\/journal.pone.0125025","DOI":"10.1371\/journal.pone.0125025"},{"key":"2023012707402124000_13.1.e067287.2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a3516e"},{"key":"2023012707402124000_13.1.e067287.3","doi-asserted-by":"publisher","DOI":"10.4065\/82.11.1341"},{"key":"2023012707402124000_13.1.e067287.4","unstructured":"National Centre for Immunisation Research and Surveillance . Significant events in zoster vaccination practice in australia. 2021. Available: https:\/\/www.ncirs.org.au\/health-professionals\/history-immunisation-australia"},{"key":"2023012707402124000_13.1.e067287.5","unstructured":"National Centre for Immunisation Research and Surveillance . Exploratory analysis of the first 2 years of adult vaccination data recorded on AIR. 2019. Available: https:\/\/www.ncirs.org.au\/sites\/default\/files\/2019-12\/Analysis%20of%20adult%20vaccination%20data%20on%20AIR_Nov%202019.pdf"},{"key":"2023012707402124000_13.1.e067287.6","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1016\/j.vaccine.2020.03.036","article-title":"Herpes zoster vaccine coverage in australia before and after introduction of a national vaccination program","volume":"38","author":"Lin","year":"2020","journal-title":"Vaccine"},{"key":"2023012707402124000_13.1.e067287.7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jinf.2022.01.011","article-title":"Impact of a national immunisation program on herpes zoster incidence in australia","volume":"84","author":"Lin","year":"2022","journal-title":"J Infect"},{"key":"2023012707402124000_13.1.e067287.8","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.vaccine.2021.01.067","article-title":"Effectiveness of the live-attenuated herpes zoster vaccine 2 years after its introduction in australia","volume":"39","author":"Lin","year":"2021","journal-title":"Vaccine"},{"key":"2023012707402124000_13.1.e067287.9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis638"},{"key":"2023012707402124000_13.1.e067287.10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu918"},{"key":"2023012707402124000_13.1.e067287.11","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwx245"},{"key":"2023012707402124000_13.1.e067287.12","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1016\/j.vaccine.2019.07.004","article-title":"Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention","volume":"37","author":"Klein","year":"2019","journal-title":"Vaccine"},{"key":"2023012707402124000_13.1.e067287.13","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw047"},{"key":"2023012707402124000_13.1.e067287.14","doi-asserted-by":"crossref","first-page":"6984","DOI":"10.1016\/j.vaccine.2017.10.067","article-title":"The effectiveness of shingles vaccine among albertans aged 50\u202fyears or older: a retrospective cohort study","volume":"35","author":"McDonald","year":"2017","journal-title":"Vaccine"},{"key":"2023012707402124000_13.1.e067287.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"2023012707402124000_13.1.e067287.16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir970"},{"key":"2023012707402124000_13.1.e067287.17","doi-asserted-by":"crossref","unstructured":"Gagliardi AM , Andriolo BN , Torloni MR , et al . Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev 2019;2019:CD008858. doi:10.1002\/14651858.CD008858.pub4","DOI":"10.1002\/14651858.CD008858.pub4"},{"key":"2023012707402124000_13.1.e067287.18","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-9-201005040-00004"},{"key":"2023012707402124000_13.1.e067287.19","doi-asserted-by":"publisher","DOI":"10.4161\/hv.7.11.17982"},{"key":"2023012707402124000_13.1.e067287.20","unstructured":"Merck Sharp & Dohme . Australian product information zostavax\u00ae zoster virus vaccine live refrigerator stable (live varicella vaccine). 2020. Available: https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2010-PI-01547-3&d=202103151016933 [Accessed 15 Mar 2021]."},{"key":"2023012707402124000_13.1.e067287.21","unstructured":"National Centre for Immunisation Research and Surveillance . Evaluation of the national shingles vaccination program process and early impact evaluation. final report. 2019. Available: http:\/\/ncirs.org.au\/sites\/default\/files\/2019-04\/ShinglesProgram Evaluation Report_1 March 2019_Final for web.pdf [Accessed 8 Dec 2020]."},{"key":"2023012707402124000_13.1.e067287.22","doi-asserted-by":"crossref","unstructured":"Costa E , Buxton J , Brown J , et al . Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient. BMJ Case Rep 2016;2016:bcr2015212688. doi:10.1136\/bcr-2015-212688","DOI":"10.1136\/bcr-2015-212688"},{"key":"2023012707402124000_13.1.e067287.23","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1016\/j.vaccine.2018.05.078","article-title":"Live zoster vaccination in an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection","volume":"36","author":"Alexander","year":"2018","journal-title":"Vaccine"},{"key":"2023012707402124000_13.1.e067287.24","unstructured":"Therapeutic Goods Administration . Therapeutics goods administration zostavax vaccine safety advisory - not to be used in patients with compromised immune function 2017. Available: https:\/\/www.tga.gov.au\/alert\/zostavax-vaccine [Accessed 1 Dec 2020]."},{"key":"2023012707402124000_13.1.e067287.25","unstructured":"Therapeutic Goods Administration . Zostavax vaccine safety advisory - not to be used in patients with compromised immune function 2020. Available: https:\/\/www.tga.gov.au\/alert\/zostavax-vaccine-0 [Accessed 1 Dec 2020]."},{"key":"2023012707402124000_13.1.e067287.26","unstructured":"Therapeutic Goods Administration . Zostavax vaccine. safety advisory - risk of infection with the vaccine virus. 2020. Available: https:\/\/www.tga.gov.au\/alert\/zostavax-vaccine-1 [Accessed 2 Mar 2021]."},{"key":"2023012707402124000_13.1.e067287.27","unstructured":"Australian Government Department of Health . Clinical update: pre-vaccination checklist for zostavax administration. 2017. Available: https:\/\/www.health.gov.au\/news\/clinical-update-pre-vaccination-checklist-for-zostavax-administration [Accessed 23 Feb 2021]."},{"key":"2023012707402124000_13.1.e067287.28","unstructured":"NSW Department of Health . Zostavax contraindications. 2017. Available: https:\/\/www.health.nsw.gov.au\/immunisation\/Documents\/GP-alert-final-version.pdf [Accessed 22 Feb 2021]."},{"key":"2023012707402124000_13.1.e067287.29","unstructured":"Australian Government Department of Health . Zostavax vaccine and immunocompromised individuals fact sheet. 2018. Available: https:\/\/www.health.gov.au\/resources\/publications\/zostavax-vaccine-and-immunocompromised-individuals-fact-sheet"},{"key":"2023012707402124000_13.1.e067287.30","unstructured":"Australian Government Department of Health . Safety alert: Zostavax vaccine. not to be used in people with compromised immune function. 2020. Available: https:\/\/www.allergy.org.au\/images\/docs\/CMO_letter_re_Zostavax_22Dec2020.pdf"},{"key":"2023012707402124000_13.1.e067287.31","unstructured":"Australian Government Department of Health . Australian immunisation handbook. 2021. Available: https:\/\/immunisationhandbook.health.gov.au"},{"key":"2023012707402124000_13.1.e067287.32","doi-asserted-by":"crossref","first-page":"529","DOI":"10.31128\/AJGP-09-21-6175","article-title":"General practitioner knowledge gaps regarding live attenuated zoster vaccination of immunocompromised individuals: an ongoing concern?","volume":"51","author":"Dey","year":"2022","journal-title":"Aust J Gen Pract"},{"key":"2023012707402124000_13.1.e067287.33","doi-asserted-by":"crossref","unstructured":"Johnson RW , Bouhassira D , Kassianos G , et al . The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 2010;8:37. doi:10.1186\/1741-7015-8-37","DOI":"10.1186\/1741-7015-8-37"},{"key":"2023012707402124000_13.1.e067287.34","unstructured":"National Centre for Immunisation Research and Surveillance . Vaccine safety. 2021. Available: https:\/\/ncirs.org.au\/health-professionals\/vaccine-safety"},{"key":"2023012707402124000_13.1.e067287.35","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002"},{"key":"2023012707402124000_13.1.e067287.36","unstructured":"World Health Organization . Global manual on surveillance of adverse events following immunization. 2016. Available: https:\/\/www.who.int\/publications\/i\/item\/10665206144"},{"key":"2023012707402124000_13.1.e067287.37","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.33321\/cdi.2020.44.12","article-title":"Surveillance of adverse events following immunisation in australia: annual report, 2018","volume":"44","author":"Dey","year":"2020","journal-title":"Commun Dis Intell (2018)"},{"key":"2023012707402124000_13.1.e067287.38","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1080\/21645515.2018.1456598","article-title":"Post-licensure safety surveillance of zoster vaccine live (zostavax\u00ae) in the united states, vaccine adverse event reporting system (VAERS), 2006-2015","volume":"14","author":"Miller","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2023012707402124000_13.1.e067287.39","doi-asserted-by":"crossref","unstructured":"Dey A , Wang H , Quinn H , et al . Surveillance of adverse events following immunisation in australia annual report, 2017. Commun Dis Intell 2018;43 doi:10.33321\/cdi.2019.43.29","DOI":"10.33321\/cdi.2019.43.29"},{"key":"2023012707402124000_13.1.e067287.40","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1016\/j.vaccine.2017.11.013","article-title":"Herpes zoster vaccine live: a 10\u202fyear review of post-marketing safety experience","volume":"35","author":"Willis","year":"2017","journal-title":"Vaccine"},{"key":"2023012707402124000_13.1.e067287.41","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1016\/j.vaccine.2012.08.070","article-title":"Safety of zostavax -- a cohort study in a managed care organization TM safety of zostavax -- a cohort study in a managed care organization","volume":"30","author":"Baxter","year":"2012","journal-title":"Vaccine"},{"key":"2023012707402124000_13.1.e067287.42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2011.02474.x"},{"key":"2023012707402124000_13.1.e067287.43","doi-asserted-by":"crossref","unstructured":"Phillips A , Glover C , Leeb A , et al . Safety of live attenuated herpes zoster vaccine in australian adults 70-79 years of age: an observational study using active surveillance. BMJ Open 2021;11:e043880. doi:10.1136\/bmjopen-2020-043880","DOI":"10.1136\/bmjopen-2020-043880"},{"key":"2023012707402124000_13.1.e067287.44","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1016\/j.vaccine.2020.03.054","article-title":"Safety of live attenuated herpes zoster vaccine in adults 70-79 years: a self-controlled case series analysis using primary care data from australia\u2019s medicineinsight program","volume":"38","author":"Totterdell","year":"2020","journal-title":"Vaccine"},{"key":"2023012707402124000_13.1.e067287.45","unstructured":"Therapeutic Goods . Zostavax vaccine: safety measures to address risk of infection with the vaccine virus. 2021. Available: https:\/\/www.tga.gov.au\/alert\/zostavax-vaccine-2"},{"key":"2023012707402124000_13.1.e067287.46","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7304"},{"key":"2023012707402124000_13.1.e067287.47","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.mayocp.2015.04.021","article-title":"Risk of herpes zoster and disseminated varicella zoster in patients taking immunosuppressant drugs at the time of zoster vaccination","volume":"90","author":"Cheetham","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"2023012707402124000_13.1.e067287.48","doi-asserted-by":"crossref","unstructured":"Grint DJ , McDonald HI , Walker JL , et al . Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis. BMJ Open 2020;10:e034886. doi:10.1136\/bmjopen-2019-034886","DOI":"10.1136\/bmjopen-2019-034886"},{"key":"2023012707402124000_13.1.e067287.49","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22196"},{"key":"2023012707402124000_13.1.e067287.50","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.190270"},{"key":"2023012707402124000_13.1.e067287.51","unstructured":"Therapeutic Goods Administration - Advisory Committee on Vaccines . ACV meeting statement, meeting 27. 2021. Available: https:\/\/www.tga.gov.au\/committee-meeting-info\/acv-meeting-statement-meeting-27-1-december-2021"},{"key":"2023012707402124000_13.1.e067287.52","unstructured":"Australian Technical Advisory Group on Immunisation . Statement on the clinical use of zoster vaccine in older adults in australia. 2021. Available: https:\/\/www.health.gov.au\/resources\/publications\/statement-on-the-clinical-use-of-zoster-vaccine-in-older-adults-in-australia"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-067287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T15:41:47Z","timestamp":1674834107000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-067287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,27]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1136\/bmjopen-2022-067287"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-067287","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}